Posts Tagged ‘cancer’

Cancer Genomics and Precision Medicine < Yale Cancer Center

June 2, 2020

https://www.dropbox.com/s/759dkp3l2alnkna/6a83d77e-30de-4b41-81b3-dc91c5b63d4a.Interview-at-Yale-Cancer-Center.x57k.mp4?dl=0

https://www.yalecancercenter.org/media-player/4956/

Somatic evolution and global expansion of an ancient transmissible cancer lineage | Science

April 14, 2020

Adrian Baez-Ortega1, Kevin Gori1,*, Andrea Strakova1,*, Janice L. Allen2, Karen M. Allum3, Leontine Bansse-Issa4, …. Michael R. Stratton62, Ludmil B. Alexandrov63, Iñigo Martincorena62, Elizabeth P. Murchison1,†

Science 02 Aug 2019:
Vol. 365, Issue 6452, eaau9923
DOI: 10.1126/science.aau9923

https://science.sciencemag.org/content/365/6452/eaau9923

Nongenic cancer-risk SNPs affect oncogenes, tumour-suppressor genes, and immune function

February 8, 2020

https://www.nature.com/articles/s41416-019-0614-3

Tobacco smoking and somatic mutations in human bronchial epithelium

February 1, 2020

https://www.nature.com/articles/s41586-020-1961-1

Tobacco smoking and somatic mutations in human bronchial epithelium

Kenichi Yoshida, Kate H. C. Gowers, Henry Lee-Six, Deepak P. Chandrasekharan, Tim Coorens, Elizabeth F. Maughan, Kathryn Beal, Andrew Menzies, Fraser R. Millar, Elizabeth Anderson, Sarah E. Clarke, Adam Pennycuick, Ricky M. Thakrar, Colin R. Butler, Nobuyuki Kakiuchi, Tomonori Hirano, Robert E. Hynds, Michael R. Stratton, Iñigo Martincorena, Sam M. Janes & Peter J. Campbell

Inherited determinants of early recurrent somatic mutations in prostate cancer | Nature Communications

December 29, 2019

Germline finding of a genetic variant that could be linked to SPOP mutations. https://www.nature.com/articles/s41467-017-00046-0

interesting perspective on cancer research in wsj + upcoming book

October 8, 2019

The focus is on improving detection vs. treatment of late stage disease.

https://www.wsj.com/articles/cancer-is-still-beating-uswe-need-a-new-start-11570206319

Attached: Cancer Therapy Advisor Q&A

March 17, 2019

February 13, 2019
Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing Bryant Furlow
https://www.cancertherapyadvisor.com/home/cancer-topics/general-oncology/qa-with-mark-b-gerstein-phd-on-diagnostic-genomic-vs-exomic-sequencing/

‘Go or grow’: the key to the emergence of invasion in tumour progression?

November 16, 2018

https://www.ncbi.nlm.nih.gov/pubmed/20610469

Sequence of events in prostate cancer

October 5, 2018

Sequence of events in prostate #cancer, by @MarkARubin1
http://www.Nature.com/articles/d41586-018-06029-5 Discusses the high prevalence of AR-enhancer amplifications in recent studies
QT:{{”
“Quigley and colleagues performed whole-genome sequencing of 101 samples of metastatic, castration-resistant prostate-cancer tissue obtained from previous studies11,12. The most frequently altered genomic site identified was the AR-enhancer region, which was amplified in 81% of samples. The high prevalence of this type of amplification is notable because enhancer amplifications identified so far for other cancer types generally arise at much lower
frequency13–16. Moreover, the high prevalence of this AR-enhancer amplification in the data presented by Viswanathan and Quigley contrasts with its occurrence in only 1 of 54 previously published whole-genome sequences of prostate-cancer samples obtained before clinical treatment had commenced17.”
“}}

The Cancer Genome Atlas: Creating Lasting Value beyond Its Data

June 15, 2018

Commentary
The Cancer Genome Atlas: Creating Lasting Value beyond Its Data Carolyn Hutter + Jean Claude Zenklusen

https://www.sciencedirect.com/science/article/pii/S009286741830374X